Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
There is a need for more effective therapy for patients following surgery for esophageal
carcinoma. Docetaxel and Irinotecan, independent of each other, have demonstrated activity in
this disease. There is interest in the combination of these two active agents plus
radiotherapy.